异甘草酸镁对慢性肝病实验室指标改善的价值

异甘草酸镁对慢性肝病实验室指标改善的价值
王柏芳;王颖;王炳元;王菲;李雪华
【期刊名称】《实用肝脏病杂志》
【年(卷),期】2012(015)003
【摘要】Objective To investigate the improvement of laboratory index by magnesium isoglycyrrhizinate (MIG) in patients with chronic liver diseases. Methods 66 patients with chronic liver diseases were treated with MIG and 129 with non-glycyrrhizic acids (non-MIG), such as with diisopropylamine dichloroacetate alone or combined with one or two kinds of hepatoprotective agents. Clinical data and laboratory results were analysed, such as the changes of blood hematology, electrolytes, coagulation and liver biochemistry for two weeks. Results Compared with non-MIG,MIG was mainly used in DILI patients '(42.4% vs 5.4%,P< 0.01);In MIG group,the level of the white blood cell(f"=0.01) and platelet (P<0.01) elevated after the first week of the treatment,and the liver enzyme (ALT,AST,ALP,and GGT) decreased significantly(P<0.01);At the initiation of the treatment,the levels of ALT,AST,GGT and ALP in MIG therapy group were 5-fold (P<0.01),2.94-fold (P<0.0l),2.41-fold(P<0.0l) and 1.63-fold(P<0.0l) higher than non-MIG group,respectively. After the two-week-treatment, they decreased to 1.53-fold(P=0.03), 1.04-fold (P=0.79), 1.29-fold (P=0.26) and 1.1-fold (P=0.33), respectively;There were almost no effects on electrolytes and coagulation indexes in MIG group (P>0.05, respectively);After two week
treatment,there were no significant differences between TP,ALB,and Hb in the two groups (P>0.05,respectively). Conclusion MIG treatment is safe and effective in patients with chronic liver injury. Compared to the control group, enzymatic indicators in MIG group shows a quick recovery and no significant side effects.%目的探讨异甘草酸镁(MIG)对慢性肝病患者实验室指标改善的价值.方法 66例应用MIG注射液(150mg/日)和129例应用非甘草酸类(非-MIG)如二氯醋酸二异丙胺注射液(80mg/日)单独或合并应用其他保肝药物治疗.观察治疗1周和2周时患者血常规、血电解质和血生化指标的变化.结果与非-MIG 治疗组比,MIG治疗l周时能升高白细胞(P=0.01),ALT、AST、AIJP和GGT降低非常明显(P<0.01).MIG开始治疗时患者ALT、AST、ALP和GGT水平分别是非-MIG治疗组患者的5倍(P<0.01)、2.94倍(P<0.01)、2.41倍(P<0.01)和1.63倍(P<0.01),治疗2周后MIG治疗组这些指标分别下降到非-MIG治疗组的1.53倍(P=0.03)、1.04倍(P=0.79)、1.29倍(P=0.26)和1.1倍(P=0.33);治疗2周
后,MIG组和非-MIG治疗组患者TP、ALB、Hb均有所下降,但两组间无统计学差异(P>0.05).结论 MIG对慢性肝损伤的治疗安全有效,血清酶学恢复迅速,未见明显的副作用.
【总页数】3页(P235-237)
【作者】王柏芳;王颖;王炳元;王菲;李雪华
【作者单位】110001,沈阳市,中国医科大学附属第一医院消化内科;110001,沈阳市,中国医科大学附属第一医院消化内科;110001,沈阳市,中国医科大学附属第一医院消化内科;110001,沈阳市,中国医科大学附属第一医院消化内科;110001,沈阳市,中国医科大学附属第一医院消化内科
【正文语种】中文
【相关文献】
1.异甘草酸镁对慢性肝病实验室指标改善的价值 [J], 王柏芳;王颖;王炳元;王菲;李雪华
2.慢性肝病应用异甘草酸镁治疗的临床效果及其对患者实验室指标的影响 [J], 张硕伟;邵花平;洪伟;刘红;魏斯友;赵海燕
3.异甘草酸镁治疗慢性肝病临床疗效及对实验室指标改善的影响 [J], 王友春
4.异甘草酸镁对慢性病毒性肝炎患者血清生化指标与临床症状的改善作用 [J], 司东晓
5.异甘草酸镁联合还原型谷胱甘肽对慢性病毒性肝炎患者肝功能及肝纤维化指标改善的影响 [J], 许光锋
因版权原因，仅展示原文概要，查看原文内容请购买。